RICERCA ITALIANA     

Programmi di ricerca simili:

• 1 - Sintesi, analisi strutturale e valutazione biologica di nuovi peptidomimetici come ligandi di integrine
• 2 - Progettazione, sintesi e attività biologica di inibitori di metalloenzimi coinvolti nelle patologie neurodegenerative, infiammatorie e tumorali.
• 3 - Polipeptidi Bioattivi e Nanostrutturati: Struttura Molecolare e Supramolecolare, Attività Biologica, Sintesi Innovative.
• 4 - NANOSISTEMI AUTOASSOCIATIVI CON RICONOSCIMENTO TRA BASI COMPLEMENTARI DI DNA/RNA
• 5 - DNA a Quadrupla Elica: Studi Strutturali e Biologici Finalizzati alla Progettazione di Nuovi Farmaci ad Attività Antitumorale o Antivirale
• 6 - Progettazione, sintesi e valutazione biologica di inibitori enzimatici e di induttori dell'apoptosi utili come agenti antitumorali
• 7 - Sintesi di sistemi nanostrutturati a base saccaridica, polivalenti e multifunzionali, per l'attivazione della risposta immunitaria
• 8 - Sviluppo di ligandi al recettore periferico delle benzodiazepine quali nuove molecole ad attività antitumorale in cellule resistenti all'induzione di apoptosi.
• 9 - Progettazione, sintesi, caratterizzazione e sviluppo di nuovi inibitori delle deacetilasi istoniche con potenziali attività traslazionali per il trattamento delle leucemie mieloidi acute
• 10 - Sviluppo di derivati chinolonici ed di altri eterocicli azotati come agenti anti-HIV: progettazione, sintesi, studio delle interazioni con nuovi target (IN, RNasi H, Tat/TAR) e modulazione della farmaco-resistenza (NNRTI)

Classificazione scientifico-disciplinare

• Area scientifico disciplinare: Scienze chimiche
  • CHIMICA ORGANICA

Classificazione brevettuale

• CHEMISTRY; METALLURGY
  • ORGANIC CHEMISTRY (such compounds as the oxides, sulfides, or oxysulfides of carbon, cyanogen, phosgene, hydrocyanic acid or salts thereof C01; products obtained from layered base-exchange silicates by ion-exchange with organic compounds such as ammonium, phosphonium or sulfonium compounds or by intercalation of organic compounds C01B33/44; macromolecular compounds C08; dyes C09; fermentation products C12; fermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture C12P; production of organic compounds by electrolysis or electrophoresis C25B3/00, C25B7/00)
    • PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

Classificazione geografica

• Regione: Lombardia

Bibliografia

[1] (a) Hynes, R.O. Integrins: Bidirectional, Allosteric Signaling Machines. Cell 2002, 110, 673. (b) van der Flier, A. et al. Function and Interactions of Integrins. Cell. Tissue Res. 2001, 305, 285
[2] (a) Clark, E.A. et al. Integrins and Signal Transduction Pathways: the Road Taken. Science, 1995, 268, 233. (b) Hood, J.D. et al. Role of Integrins in Cell Invasion and Migration. Nat. Rev. Cancer 2002, 2, 91. (c) Giancotti, F.G. et al. Science 1999, 285, 1028. (d) Stupack, D.G. et al. J. Cell. Sci. 2002, 115, 3729. (e) Frisch, S.M. et al. Curr. Opin. Cell. Biol. 1997, 9, 701
[3] Danen, E.H.J. Integrins: Regulators of Tissue Function and Cancer Progression. Curr. Pharm. Des. 2005, 11, 881
[4] (a) Plantefaber, L.C. et al. Changes in Integrin Receptors on Oncogenically Transformed Cells. Cell 1989, 56, 281. (b) Felding-Habermann, B. et al. Involvement of Integrin AlphaV Gene Expression in Human Melanoma Tumorigenicity. J. Clin. Invest. 1992, 89, 2018. (c) Mizejewski, G.J. Proc. Soc. Exp. Biol. Med. 1999, 222, 124
[5] (a) Hanahan, D. et al. The Hallmarks of Cancer. Cell 2000, 100, 57. (b) Kerbel, R. et al. Clinical Translation of Angiogenesis Inhibitors. Nat. Rev. Cancer 2000, 2, 727. (c) Curley, G.P. et al. Cell. Mol. Life Sci. 1999, 56, 427
[6] Yusuf-Makagiansar, H. et al. Inhibition of LFA-1/ICAM-1 and VLA-4/VCAM-1 as a Therapeutic Approach to Inflammation and Autoimmune Disease. Med. Res. Rev. 2002, 22, 146
[7] Wang, J.H. et al. The Crystal Structure of the N-Terminal Two-Domain Fragment of Vascular Cell Adhesion Molecule 1 (VCAM-1): A Cyclic Peptide Based on the Domain 1 C-D Loop Can Inhibit VCAM-1-alpha4 Integrin Interaction. PNAS 1995, 92, 5714
[8] (a) Viney, J.L. et al. Mucosal Addressin Cell Adhesion Molecule-1 - a Structural and Functional Analysis Demarcates the Integrin Binding Motif. J. Immunol. 1996, 157, 2488. (b) Sandborn, W.J. et al. Novel Approaches to Treating Inflammatory Bowel Disease: Targeting Alpha-4 Integrin. Am. J. Gastroenterol. 2003, 98, 2372
[9] (a) Samanen, J. et al. Development of a Small RGD Peptide Fibrinogen Receptor Antagonist with Potent Antiaggregatory Activity in Vitro. J. Med. Chem. 1991, 34, 3114. (b) Bach, A.C., II et al. Type II’ to Type I Beta-Turn Swap Changes Specificity for Integrins. J. Am. Chem. Soc. 1996, 118, 293. (c) Haubner, R. et al. Angew. Chem. Int. Ed. 1997, 36, 1374
[10] (a) Dechantsreiter, M.A. et al. N-Methylated Cyclic RGD Peptides as Highly Active and Selective AlphaVbeta3 Integrin Antagonists. J. Med. Chem. 1999, 42, 3033 (b) Jonczyk, A. et al. Preparation of Cyclic Peptides as Integrin Inhibitors. Ger. Offen. DE19534177 A1, 1997. (c) Jonczyk, A. et al. PCT Int. Appl. WO 2000015244 A2, 2000
[11] Xiong, J.-P. et al. Crystal Structure of the Extracellular Segment of Integrin AlphaVbeta3. Science 2001, 294, 339
[12] Xiong, J.-P. et al. Crystal Structure of the Extracellular Segment of Integrin AlphaVbeta3 in Complex with an Arg-Gly-Asp Ligand. Science 2002, 296, 151
[13] (a) Belvisi, L. et al. Potent Integrin Antagonists from a Small Library of RGD-Including Cyclic Pseudopeptides. Org. Lett. 2001, 3, 1001. (b) Scolastico, C. et al. Preparation of Peptidomimetic Azabicycloalkane Compounds Containing the RGD Sequence for Use as Integrin Inhibitors. PCT Int. Appl. WO 2005007654 A1, 2005. (c) Scolastico, C. et al. PCT Int. Appl. WO 2005042531 A1, 2005. (d) Belvisi, L. et al. Mol. Cancer Ther. 2005, 4, 1670
[14] (a) Casiraghi, G. et al. Grafting Aminocyclopentane Carboxylic Acids onto the RGD Tripeptide Sequence Generates Low Nanomolar AlphaVbeta3/AlphaVbeta5 Integrin Dual Binders. J. Med. Chem. 2005, 48, 7675. (b) Casiraghi, G. et al. Ciclopeptidi Ibridi Contenenti Amminoacidi Cicloalcanici, e Loro Preparazione ed Uso. Ital. Pat. Appl. RE2005A00088, 2005
[15] Miller, W.H. et al. Orally Bioavailable Nonpeptide Vitronectin Receptor Antagonists with Efficacy in an Osteoporosis Model. Bioorg. Med. Chem. Lett. 1999, 9, 1807
[16] (a) Shimaoka, M. et al. Conformational Regulation of Integrin Structure and Function. Annu. Rev. Biophys. Biomol. Struct. 2002, 31, 485. (b) Tilley, J.W. et al. The Discovery of VLA-4 Antagonists. Curr. Top. Med. Chem. 2004, 4, 1509
[17] Hynes, R.O. A Reevaluation of Integrins as Regulators of Angiogenesis. Nature Med. 2002, 8, 918
[18] (a) Chen, X. et al. Synthesis and Biological Evaluation of Dimeric RGD Peptide-Paclitaxel Conjugate as a Model for Integrin-Targeted Drug Delivery. J. Med. Chem. 2005, 48, 1098. (b) Nasongkla, N. et al. cRGD-Functionalized Polymer Micelles for Targeted Doxorubicin Delivery. Angew. Chem. Int. Ed. 2004, 43, 6323
[19] (a) Achilefu, S. et al. Synergistic Effects of Light-Emitting Probes and Peptides for targeting and Monitoring Integrin Expression. PNAS 2005, 102, 7976. (b) Ye, Y. et al. Design, Synthesis and Evaluation of Near Infrared Fluorescent Multimeric RGD Peptides for Targeting Tumors. J. Med. Chem. 2006, 49, 2268. (c) Achilefu, S. Technol. Cancer Res. Treat. 2004, 3, 393. (d) Chen, X. et al. Cancer Res. 2004, 64, 8009. (e) Wang, W. et al. Mol. Imaging 2004, 3, 343. (f) Burnett, C.A. et al. Bioorg. Med. Chem. 2005, 13, 3763
[20] (a) Haubner, R. et al. Radiolabeled AlphaVbeta3 Integrin Antagonists: a New Class of Tracers for Tumor Targeting. J. Nucl. Med. 1999, 40, 1061. (b) Haubner, R. et al. Noninvasive Visualization of the Activated AlphaVbeta3 Integrin in Cancer Patients by Positron Emission Tomography and [18F]Galacto-RGD. PLoS Med. 2005, 2, 244. (c) Haubner, R. et al. Bioconjug. Chem. 2004, 15, 61. (d) Janssen, M.L. et al. Cancer Res. 2002, 62, 6146. (e) Chen, X. et al. Mol. Imaging Biol. 2004, 6, 350. (f) Chen, X. et al. J. Nucl. Med. 2004, 45, 1776. (g) Chen, X. et al. Bioconjugate Chem. 2004, 15, 41. (h) Haubner, R. et al. J. Nucl. Med. 2001, 42, 326. (i) Liu. S. et al. Bioconjugate Chem. 2001, 12, 624. (j) Su, Z.-F. et al. Nucl. Med. Biol. 2003, 30, 141
[21] Capello, A. et al. Increased Cell Death After Therapy with an Arg-Gly-Asp-Linked Somatostatin Analog. J. Nucl. Med. 2004, 45, 1716.
[22] (a) Kessler, H. et al. Molecular Targeting with Peptides or Peptide-Polymer Conjugates: Just a Question of Size? J. Nucl. Med. 2005, 46, 1940. (b) Garanger, E. et al. New Multifunctional Molecular Conjugate Vector for Targeting. Imaging, and Therapy of Tumors. Mol. Ther. 2005, 12, 1168. (c) Boturyn, D. et al. J. Am. Chem. Soc. 2004, 126, 5730. (d) Kok, R.J. et al. Bioconjugate Chem. 2002, 13, 128. (e) Biesalski, M.A. et al. Biomaterials 2006, 27, 1259. (f) Boturyn, D. et al. Tetrahedron Lett. 2001, 42, 2787
[23] Jemal, A. et al. Cancer Statistics, 2002. CA Cancer J. Clin. 2002, 52, 23
[24] Jordan, M.A. Mechanism of Action of Antitumor Drugs that Interact with Microtubules and Tubulin. Curr. Med. Chem: Anti-Cancer Agents 2002, 2, 1
[25] (a) Altmann, K.-H. Microtubule-Stabilizing Agents: a Growing Class of Important Anticancer Drugs. Curr. Opin. Chem. Biol. 2001, 5, 424. (b) Myles, D.C. Emerging Microtubule Stabilizing Agents for Cancer Chemotherapy. Ann. Rep. Med. Chem. 2002, 37, 125
[26] (a) Gennari, C. et al. Method for the Preparation of Taxol and its Derivatives. WO 97 00870, 1997. (b) Gennari, C. et al. Paclitaxel (Taxol®) Semisynthesis: A Highly Enantio- and Diastereoselective Synthesis of the Side Chain and a New Method for (C-13) OH Esterification Using Thioesters. Angew. Chem. Int. Ed. Engl. 1996, 35, 1723; J.Org.Chem. 1997, 62, 4746. (c) Gennari, C. et al. A Formal Total Synthesis of Eleutherobin Through an Unprecedented Kinetically Controlled Ring-Closing-Metathesis Reaction. Angew. Chem. Int. Ed. 2005, 44, 588; Chem.Eur.J. 2006, 12, 51. (d) Gennari, C. et al. Tetrahedron 2005, 61, 2123
[27] Novartis AG, Annual Report, file n. 1-15024, Form 20-F, Jan. 28, 2005, p.42
[28] Monaghan, S. et al. Solid-Phase Synthesis of Peptide-Dendrimer Conjugates for an Investigation of Integrin Binding. ARKIVOK 2001, 46
[29] Auernheimer, J. et al. Photoswitched Cell Adhesion on Surfaces with RGD Peptides. J. Am. Chem. Soc. 2005, 127, 16107

Parole Chiave

SINTESI ORGANICA, SINTESI STEREOSELETTIVA, AMMINOACIDI NON NATURALI, PEPTIDOMIMETICI, LIGANDI DELLE INTEGRINE, SINTESI DI COMPOSTI ANTITUMORALI, SINTESI DI AGENTI DI CONTRASTO PER IMAGING, MARCATURA CON RADIOISOTOPI, MOLECOLE FOTOMODULABILI